Metformina Cinfa (Metformin Hydrochloride)

Metformin reduces hepatic glucose production by inhibiting gluconeogenesis, increases peripheral insulin sensitivity, and modestly decreases intestinal glucose absorption. These actions collectively lower fasting and post‑prandial blood glucose levels without directly stimulating insulin secretion.

The specific dosage and titration schedule for Metformina Cinfa are determined by the prescribing clinician based on the individual’s renal function, glycemic targets, and overall health status. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Metformina Cinfa is classified as pregnancy category unknown in many regions. It may be used during pregnancy when the potential benefit outweighs risk, such as in gestational diabetes, but this decision rests with the obstetrician. Metformin does pass into breast milk in small amounts; breastfeeding mothers should discuss continuation with their healthcare provider.

To request Metformina Cinfa, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Metformina Cinfa (metformin) belongs to the biguanide class and is often first‑line therapy because it improves insulin sensitivity without causing weight gain. Compared with sulfonylureas, it has a lower risk of hypoglycemia, and unlike insulin, it is administered orally. Its efficacy is well‑established, and it is generally less expensive than newer agents such as GLP‑1 receptor agonists.

Metformina Cinfa should be stored at room temperature, below 25 °C, in the original packaging to protect it from moisture and light. Keep the product out of reach of children and do not use if the tablet shows signs of damage or discoloration.

Metformina Cinfa is taken orally, usually with meals to reduce gastrointestinal upset. The tablets are swallowed whole with a full glass of water. Patients should not crush, chew, or split extended‑release formulations unless specifically instructed by a healthcare professional.

The most serious adverse reaction is lactic acidosis, a rare but potentially fatal condition that can occur in patients with severe renal or hepatic impairment, hypoxia, or excessive alcohol intake. Other serious risks include severe skin reactions such as Stevens‑Johnson syndrome and significant vitamin B12 deficiency with long‑term use.

Metformina Cinfa is contraindicated in patients with severe renal impairment (eGFR < 30 mL/min/1.73 m²), acute or chronic metabolic acidosis, including diabetic ketoacidosis, and known hypersensitivity to metformin or any component of the formulation. Caution is also advised for individuals with liver disease, heart failure, or a history of lactic acidosis.